You have 9 free searches left this month | for more free features.

nab-paclitaxel

Showing 1 - 25 of 338

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Breast Cancer Trial (RO7247669, Pembrolizumab, Nab-Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
May 2, 2023

TNBC Trial in Shanghai (PM8002, nab-paclitaxel)

Recruiting
  • TNBC
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 25, 2023

Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)

Not yet recruiting
  • Breast Neoplasms
  • Hangzhou, Zhejiang, China
    ZhejiangCH
Nov 17, 2023

HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)

Not yet recruiting
  • HR+/HER2- Breast Cancer
  • (no location specified)
Nov 21, 2022

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023

Pancreatic Cancer Trial in New York (Canakinumab, Tislelizumab, Nab-Paclitaxel)

Recruiting
  • Pancreatic Cancer
  • New York, New York
  • +2 more
Aug 2, 2023

Pancreatic Cancer Trial in Boston, Philadelphia (Gemcitabine, Nab-paclitaxel, Paricalcitol)

Active, not recruiting
  • Pancreatic Cancer
  • Boston, Massachusetts
  • +1 more
Jan 9, 2023

Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB Trial in Shanghai (sintilimab,

Not yet recruiting
  • Pancreatic Cancer, Stage IB
  • +3 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Jan 4, 2023

Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma Trial in Indianapolis (Lonsurf, Gemcitabine, Nab-Paclitaxel)

Active, not recruiting
  • Pancreatic Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Indianapolis, Indiana
    Indiana University Melvin & Bren Simon Cancer Center
Nov 29, 2022

Triple Negative Breast Cancer Metastatic Trial in Milano, Padova (Ceralasertib, Durvalumab, Nab-paclitaxel)

Recruiting
  • Triple Negative Breast Cancer Metastatic
  • Milano, Italy
  • +1 more
Jan 16, 2023

Soft Tissue Sarcoma Trial in Switzerland (Nab-Paclitaxel, gemcitabine)

Terminated
  • Soft Tissue Sarcoma
  • Basel, Switzerland
  • +7 more
Sep 27, 2022

Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)

Completed
  • Breast Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 20, 2022

Pancreatic Adenocarcinoma, Metastatic Trial in Spain, United States (Nab-paclitaxel, Gemcitabine, VCN-01)

Not yet recruiting
  • Pancreatic Adenocarcinoma
  • Metastatic
  • Nab-paclitaxel
  • +2 more
  • New York, New York
  • +7 more
Jan 3, 2023

Pancreatic Ductal Adenocarcinoma Trial in Saint Louis (BMS-813160, Nivolumab, Gemcitabine)

Active, not recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Dec 8, 2022

Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic

Active, not recruiting
  • Breast Cancer
  • New York, New York
    NYU Perlmutter Cancer Center
Aug 5, 2022

Breast Cancer Trial in Boston (Pembrolizumab, Nab-Paclitaxel, Biopsy)

Active, not recruiting
  • Breast Cancer
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Aug 22, 2022

NSCLC Trial in Boston, New York (MPDL3280A, Carboplatin, Nab-paclitaxel)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Boston, Massachusetts
  • +1 more
Oct 12, 2022

NSCLC Trial in Shanghai (Pembrolizumab, Paclitaxel, Nab-paclitaxel)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +4 more
  • Shanghai, China
    Zhongshan Hospital Fudan University
Aug 18, 2022

Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8 Trial

Recruiting
  • Borderline Resectable Pancreatic Adenocarcinoma
  • +5 more
  • Durvalumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Metastatic Breast Cancer Trial in Shanghai (Sitravatinib, Tislelizumab, Nab-paclitaxel)

Recruiting
  • Metastatic Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer
Jul 31, 2022

Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma Trial in Beverly Hills, Los Angeles

Recruiting
  • Advanced Pancreatic Adenocarcinoma
  • +2 more
  • Beverly Hills, California
  • +1 more
Jun 16, 2022

Solid Tumor, TNBC - Triple-Negative Breast Cancer Trial in Bengbu, Beijing (LAE005 + Afuresertib + Nab-Paclitaxel, LAE005 +

Recruiting
  • Solid Tumor
  • TNBC - Triple-Negative Breast Cancer
  • LAE005 + Afuresertib + Nab-Paclitaxel
  • +3 more
  • Bengbu, Anhui, China
  • +1 more
May 19, 2022

Pancreatic Cancer Trial in Baltimore, Dallas (ARQ-761, Gemcitabine, nab-paclitaxel)

Terminated
  • Pancreatic Cancer
  • Baltimore, Maryland
  • +1 more
May 31, 2022

Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma Trial in United States (Laboratory

Active, not recruiting
  • Locally Advanced Breast Carcinoma
  • +7 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Duarte, California
  • +3 more
Jan 31, 2023

NSCLC, Squamous Cell Carcinoma Trial in Wuhan (Nab-paclitaxel, Carboplatin, Thoracic radiation therapy)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Squamous Cell Carcinoma
  • Nab-paclitaxel
  • +2 more
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Apr 26, 2022